1. Introduction
===============

Epidermal growth factor receptor (EGFR) is a receptor protein, which consists of 486 amino acids and 170 kDa in size. It possesses a single trans-membrane sequence among the extracellular and intracellular domains.^\[[@R1]\]^ Recent studies have indicated that patients diagnosed with lung adenocarcinoma and EGFR mutation can obtain clinical benefits from the target therapy of gefitinib. Lung adenocarcinoma can harbor EGFR mutation, which is a protein on cell surface with intracellular tyrosine kinase (TK) activity. Due to targetable activating mutations, tumors are susceptible to erlotinib and gefitinib.^\[[@R2]\]^ It has been reported that 3% to 5% of lung adenocarcinoma patients carry the translocations of the anaplastic lymphoma kinase (ALK) gene. The most common translocation leads to an aberrant fusion between the microtubule-associated protein-like 4 gene (EML4) and ALK. This event contributes to the formation of cytoplasmic chimeric protein, which provokes the oncogenic signaling pathway and serves as a therapeutic target. Compared with the second-line single agent chemotherapy, crizotinib chemotherapy can prolong the progression-free survival and enhance the objective response rate.^\[[@R3]\]^

In the year of 2011, American Thoracic Society, International Association for the Study of Lung Cancer, and European Respiratory Society jointly proposed a novel classification of lung adenocarcinoma which included multiple modifications to the previous classification criterion.^\[[@R4]\]^ This classification now considers sample resection, small biopsy, and cytological specimens. Bronchioloalveolar cancer and mixed-subtype adenocarcinoma are not utilized. Invasive adenocarcinomas can be classified into the acinar, lepidic, solid, papillary, and micropapillary patterns, which offer instructions for cytological specimens and small biopsy. In this investigation, the correlation between the mutation of EML4-ALK and EGFR, and the clinicopathological features was evaluated in 90 patients diagnosed with lung adenocarcinoma.

2. Materials and methods
========================

2.1. Specimen collection
------------------------

The excisional samples of 90 lung adenocarcinoma patients admitted to the First Affiliated Hospital of Xi'an Jiaotong University between September 2011 and December 2014 were retrospectively analyzed. All specimens were fixed in 4% neutral formalin solution, paraffin embedding and prepared for subsequent immunohistochemical staining. Informed consents were obtained from all participants in this investigation. The study procedures comply with the ethics committee of Xi'an Jiaotong University.

2.2. Clinicopathological features
---------------------------------

Clinicopathological parameters including age, gender, smoking history, clinical staging, histological subtype, tumor size, pleural invasion, and lymphatic metastasis were recorded. The HE staining sections were examined and reviewed for histological subtyping strictly according to IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma, as illustrated in Figure [1](#F1){ref-type="fig"}.

![Histological type of infiltrative lung adenocarcinoma (HE ×20). (A) Lepidic subtype; (B) acinar subtype; (C) papillary subtype; (D) micropapillary subtype; (E) solid subtype complicated with mucin secretion; (F) infiltrative mucus adenocarcinoma.](medi-97-e11116-g001){#F1}

2.3. Detection of EML4-ALK fusion gene mutation
-----------------------------------------------

The findings of Ventana immunohistochemical staining were re-evaluated according to the revised diagnostic criteria of nonsmall cell lung cancer with positive ALK proposed by Chinese Society of Clinical Oncology in 2013.^\[[@R5]\]^ ALK mutation was defined as the strong staining of the granule cellular cytoplasm in the tumor cells, no staining was considered as wild type.

2.4. DNA extraction and EGFR gene mutation
------------------------------------------

The 4-μm thick sections were placed into 1.5-mL centrifuge tube, dewaxing using xylene and supplemented with 1-mL absolute ethyl alcohol, gently mixed and maintained at room temperature for 5 minutes and subsequently centrifuged at 14000 *r*/min for 3 minutes. The supernatant was discarded. Absolute ethyl alcohol was added to eliminate the xylene. The tube was open and maintained at room temperature to thoroughly volatilize the ethanol. DNA extraction was performed strictly according to the manufacturers' instructions (Qiagen DNA mini kit, serial No. 51304). The concentration and purity of DNA were assessed at the wavelength of OD260 and OD260/OD280. The mutation of EGFR was detected by using the amplification refractory mutation system (ARMS) from Amoy Diagnostics Co., Ltd. (Xiamen, China). Quantitative PCR amplification was performed using BIO-RAD CFX96 PCR system.

2.5. Statistical analysis
-------------------------

All statistical analysis was performed using SPSS 20.0 statistical software (SPSS Inc., Chicago) and SAS software (Statistical analysis system, SAS Institute Inc.). Enumeration data were statistically compared using chi-square test. When 1≤T\<5, continuously-corrected chi-square test was conducted. Paired enumeration data were statistically compared using McNemar chi-square test. When *T* \< 1, Fisher exact test was performed using the SAS statistical software. A *P* value of \< .05 was considered as statistical significance.

3. Results
==========

3.1. Baseline data
------------------

Ninety patients were diagnosed with infiltrative or mutated adenocarcinoma including 8 (8.9%) with lepidic lung adenocarcinoma, 51 (56.7%) with acinar lung adenocarcinoma, 11 (12.2%) with papillary lung adenocarcinoma, 3 (3.3%) with micropapillary lung adenocarcinoma, 11 (12.2%) with solid subtype complicated with mucin secretion and 6 (6.7%) with infiltrative mucus adenocarcinoma, as illustrated in Figure [1](#F1){ref-type="fig"}.

3.2. Vetana immunohistochemical staining of EML4-ALK
----------------------------------------------------

The positive rate of EML4-ALK fusion gene mutation was calculated as 6.7% (6/90), as revealed in Figure [2](#F2){ref-type="fig"}. Six (14.6%) among 41 patients aged \< 60 years had EML4-ALK fusion gene mutation, significantly higher than 0.0% in 49 cases aged ≥ 60 years who had no EML4-ALK fusion gene mutation (*P* = .019), prompting that the mutation rate of EML4-ALK fusion gene in patients aged \< 60 years was relatively high. No correlation was documented between EML4-ALK gene mutation and gender, smoking history, maximal tumor size, pleural invasion, lymphatic metastasis or clinical staging, as illustrated in Table [1](#T1){ref-type="table"}.

![Ventana immunohistochemical staining of ALK (×200). (A) Solid adenocarcinoma with mucin secretion; (B) acinar adenocarcinoma.](medi-97-e11116-g002){#F2}

###### 

Correlation among EML4-ALK gene fusion status, EGFR gene mutation, and clinical parameters.
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3.3. Correlation between EML4-ALK fusion gene and histological subtype
----------------------------------------------------------------------

Among 51 patients with acinar histological subtype, 5 (9.8%) had EML4-ALK fusion gene mutation. One among 11 cases (9.1%) of solid subtype complicated with mucin secretion had EML4-ALK fusion gene mutation. No EML4-ALK fusion gene mutation was noted in alternative histological subtypes. The positive rate of EML4-ALK fusion gene mutation significantly differed among different histological subtypes (*P* = .042), as illustrated in Table [2](#T2){ref-type="table"}.
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Correlation among EML4-ALK gene fusion status, EGFR gene mutation, and histological subtype.
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3.4. EGFR gene mutation
-----------------------

Among 90 patients diagnosed with lung adenocarcinoma, 45 received EGFR mutation detection and 27 were detected to have EGFR mutation with a positive rate of EGFR mutation of 60%, as illustrated in Figure [3](#F3){ref-type="fig"}.

![Signaling graph of EGFR gene mutation. (A) Internal control signal; (B) external and mutation signals.](medi-97-e11116-g005){#F3}

3.5. Correlation between EGFR gene mutation and clinicopathological parameters
------------------------------------------------------------------------------

The positive rate of EGFR gene mutation in male patients was calculated as 38.9% (7/18), significantly lower compared with 74.1% (20/27) in their female counterparts (*P* = .018). The positive rate of EGFR gene mutation in smokers was calculated as 37.5% (6/16), significantly lower compared with 72.4% (21/29) in the nonsmokers (*P* = .022). The median tumor size was selected for grouping because the maximal tumor size was abnormally distributed. In the patients with tumor size \< 3 cm, the positive rate of EGFR gene mutation was 78.9% (15/19), considerably higher compared with 46.2% (12/26) in their counterparts with tumor size≥3 cm (*P* = .027). As illustrated in Table [1](#T1){ref-type="table"}, EGFR gene mutation was not associated with age, gender, pleural invasion, lymphatic metastasis, or clinical staging.

3.6. Correlation between EGFR gene mutation and histological subtype
--------------------------------------------------------------------

Among 90 patients with lung adenocarcinoma, 45 cases received EGFR gene detection. In this subgroup, the positive rate of EGFR gene mutation in patients with predominant patterns of micropapillary, lepidic, and papillary subtypes was relatively higher compared with that in other types (*P = *.000), as illustrated Table [2](#T2){ref-type="table"}.

4. Discussion
=============

In recent years, significant progression has been obtained in the molecular biological research of lung adenocarcinoma, especially for lung adenocarcinoma patients complicated with EGFR, KRAS, and EMIA-ALK mutation. It has been demonstrated that lung adenocarcinoma patients complicated with EGFR and EML4-ALK are susceptible to the target therapy of gefitinib, significantly enhancing the clinical prognosis. Previous studies have found that the specific histological components are associated with certain molecular changes.

In this investigation, EML4-ALK gene mutation was mainly observed in patients aged \< 60 years, which is consistent with previous findings.^\[[@R6]\]^ Shaw et al^\[[@R7]\]^ reported that the positive rate of EML4-ALK fusion gene mutation in male patients was 22.9%, significantly higher compared with 8.6% in female counterparts. However, no correlation was documented between EML4-ALK gene mutation and gender in our study. This discrepancy probably results from that the fact that sampling screening or relatively low positive rate of EML4-ALK fusion gene in the study of Shaw. In addition, the sampling size in present investigation is insufficient, which may lead to data deviation. The association between EML4-ALK fusion gene and smoking history remains elusive. Previous studies of Western population have demonstrated that the positive rate of EML4-ALK fusion gene mutation in smokers is significantly lower compared with that in nonsmokers.^\[[@R7],[@R8]\]^ However, in this study, we found no correlation between EML4-ALK fusion gene and smoking history in Chinese. We hypothesized that the difference in the association between EML4-ALK fusion gene and smoking history probably results from the population disparity. Moreover, no apparent association was noted among EML4-ALK fusion gene mutation, maximal tumor size, lymphatic metastasis, and tumor staging, which is consistent with previous investigations.^\[[@R7],[@R9],[@R10]\]^

Prior to the introduction of IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma, WHO classification criterion is mainly adopted to evaluate the relationship between histological type of lung adenocarcinoma and EML4-ALK fusion gene. In Western population, EML4-ALK fusion gene mutation is mainly detected in patients diagnosed with solid adenocarcinoma and signet-ring cell lung carcinoma. Although histological subtype does not significantly differ, the positive rate of EML4-ALK fusion gene mutation in patients with\>10% of solid adenocarcinoma complicated with signet-ring cell carcinoma is significantly higher compared with those in alternative histological subtypes.^\[[@R11]\]^ In Asian population, Jokoji et al^\[[@R12]\]^ and Sakairi et al^\[[@R10]\]^ have demonstrated that EML4-ALK fusion gene mutation is dominantly detected in patients with mucus adenocarcinoma and cribriform adenocarcinoma complicated with a high quantity of extracellular mucus. Nevertheless, after the release of IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma, EML4-ALK fusion gene mutation is mainly detected in patients with micropapillary, acinar and infiltrative mucus adenocarcinoma. In current investigation, EML4-ALK fusion gene mutation is dominantly detected in patients with acinar and solid adenocarcinoma complicated with mucus, which is consistent with previous findings.^\[[@R13]\]^

In this study, EGFR gene mutation is preferentially detected in the female patients, nonsmokers and those with maximal tumor size \< 3 cm, whereas it is not correlated with age, pleural invasion, lymphatic metastasis or tumor staging, which is almost consistent with previous findings.^\[[@R14]\]^ After the release of IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma, previous investigations have demonstrated that EGFR gene mutation is mainly detected in patients with lepidic, papillary, micropapillary, and acinar subtypes, whereas the mutation rate is extremely low in patients with solid adenocarcinoma, which is almost consistent with the outcomes of current study.^\[[@R15]\]^ Yoshizawa et al^\[[@R16]\]^ reported that EGFR gene mutation is commonly detected in patients diagnosed with in situ adenocarcinoma and infiltrative micro-adenocarcinoma. These findings imply that IASLC/ATS/ERS international multidisciplinary classification of lung adenocarcinoma can reflect the gene typing of lung adenocarcinoma. Yang et al^\[[@R17]\]^ quantitatively investigated the CT scan characteristics, which are correlated with the mutations of 3 driver genes in patients diagnosed with lung adenocarcinomas patients in a Chinese cohort and have demonstrated that it is important to understand ground-glass opacity lesions in patients with lung adenocarcinomas and explore relevant molecular biomarkers, which can add new evidence to select the optimal therapy for lung adenocarcinoma with ground-glass opacity lesions revealed by CT scan. Nakamura et al^\[[@R18]\]^ have analyzed the relationships between the subtypes and EGFR, and have found that the outcomes after the lung adenocarcinoma was fully removed can be predicted according to the subtype classification. Since EGFR mutations can be detected in all subtypes, it is essential to perform the mutation analysis for selecting the recurrent patients who can be effectively treated with EGFR-tyrosine kinase inhibitor.

Nevertheless, the findings of current investigation remain to be validated by subsequent research with larger sample size. Besides, the survival data of the lung adenocarcinoma patients should be further confirmed by more investigations.

5. Conclusion
=============

To conclude, the mutation rate of EML4-ALK fusion gene is relatively high in patients aged \< 60 years, acinar and solid subtypes complicated with mucin secretion. Meantime, the positive rate of EGFR gene mutation is higher in female patients, nonsmokers, those with maximal tumor size \< 3 cm, micropapillary, lepidic, papillary, and acinar subtypes of lung adenocarcinoma compared with their counterparts.
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